Clinical trials: Active Acne
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety.
- Trial name
- NCT02578043
- Testing
- Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%, Onexton™ Gel
- Volunteers
- 844 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne
A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to the already marketed formulation, Acanya gel in…
- Trial name
- NCT01796665
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%, Acanya Gel
- Volunteers
- 1,180 people
- Sponsor
- Padagis LLC
Acne Vulgaris
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of…
- Trial name
- NCT06673641
- Testing
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.
- Trial name
- NCT03433378
- Testing
- Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
- Trial name
- NCT04797793
- Testing
- Adapalene Gel 0.1%, Differin® Gel (Adapalene 0.1%, Galderma)
- Where
- United States
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne, Peeling
Efficacy of Different Types of Chemical Peels in the Treatment of Acne Vulgaris
Assessment of the Efficacy and Safety of 50% Glycolic Acid, 30% Salicylic Acid, and Modified Jessner's Chemical Peels in the Treatment of Active Acne and Post-acne Hyperpigmentation: Randomized Controlled Trial.
- Trial name
- AV (NCT07240051)
- Testing
- Glycolic acid peel alone, salicylic acid, modified jessener
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Nahla Maher Mahmoud Mahran
Acne Vulgaris
Acne Treatment With Active Oplon's Patches - 15-18 Years Old
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.
- Trial name
- NCT01260766
- Testing
- Oplon Active Patch
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Oplon-Pure Science Ltd.
Acne Vulgaris
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that : CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects CD0271…
- Trial name
- NCT01880320
- Testing
- CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
- Where
- 31 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
- Trial name
- NCT04015375
- Testing
- Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
- Where
- 13 sites in United States, Belize
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.
- Trial name
- NCT03427554
- Testing
- Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
- Where
- United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
- Trial name
- NCT02411942
- Testing
- Adapalene Gel 0.3%, Differin®
- Volunteers
- 753 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris, Acne
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel, Tretinoin Gel and Vehicle Gel for the treatment of…
- Trial name
- NCT00689117
- Testing
- CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin)
- Where
- 32 sites in United States, Belize and 1 more
- Volunteers
- 1,649 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.
- Trial name
- NCT02865005
- Testing
- Dapsone 5.0% Gel (SEEGPharm), Dapsone 5.0% Gel (Allergan)
- Where
- 36 sites in United States, Belize
- Volunteers
- 2,361 people
- Sponsor
- Seegpharm S.A.
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
- Trial name
- NCT06063473
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
- Where
- United States
- Volunteers
- 762 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of…
- Trial name
- NCT02661958
- Testing
- S6G5T-3, S6G5T-1, S6G5T-5
- Where
- 34 sites in United States
- Volunteers
- 726 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel…
- Trial name
- NCT01769235
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Acanya® Gel, 1.2%/2.5%, Vehicle of test product
- Volunteers
- 1,215 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.